LinkedIn facebook twitter youtube
News archive
Recent news

The contribution of patients and patient experts provides tangible value to other stakeholders and society that should be fairly compensated. Currently, there is no transparent and consistent system for financial compensation in place that reflects the level of individual contribution and expertise.

For this reason the Workgroup of European Cancer Patient Advocacy Networks (WECAN) is running a survey to find out what the compensation should be for the contribution of patient advocates. MPE is a WECAN member along with other 20 European cancer patient umbrella organisations and it is also part of the WECAN Fair Market Value workgroup represented by the CEO of MPE, Ananda Plate.

Compensation in the context of this survey means honoraria or other compensation by third parties (no patient organisations) for individual tasks such as advisory boards, doing presentations, providing substantial feedback, reviewing complex documents etc. Reimbursement of travel cost, daily allowances for expenses etc. do not count as financial compensation for tasks.

Find more information about the rationale behind this survey in this link http://www.wecanadvocate.eu/wecan-survey-on-fair-market-value. If you are a patient advocate, please, respond this survey before 26 August by clicking here.

Your responses will help WECAN to formulate a clear recommendation on the current debate about “Fair Market Value” for the benefit of our patient advocacy community.

Recent news

» MPE Publishes 2021: Year in Review

» ASH 2021| over 50% of myeloma patients reach minimal residual disease negativity with Isatuximab in combination with RVd

Leave a Reply

Your email address will not be published. Required fields are marked *

I accept the Privacy Policy